Market Research Logo

Aspergillosis - Pipeline Review, H1 2015

Aspergillosis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Aspergillosis - Pipeline Review, H1 2015’, provides an overview of the Aspergillosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Aspergillosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Aspergillosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Aspergillosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Aspergillosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Aspergillosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Aspergillosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Aspergillosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Aspergillosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Aspergillosis Overview
Therapeutics Development
Pipeline Products for Aspergillosis - Overview
Pipeline Products for Aspergillosis - Comparative Analysis
Aspergillosis - Therapeutics under Development by Companies
Aspergillosis - Therapeutics under Investigation by Universities/Institutes
Aspergillosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Aspergillosis - Products under Development by Companies
Aspergillosis - Products under Investigation by Universities/Institutes
Aspergillosis - Companies Involved in Therapeutics Development
Amplyx Pharmaceuticals, Inc.
Astellas Pharma Inc.
Aureogen Biosciences, Inc.
Basilea Pharmaceutica AG
Biomar Microbial Technologies
Eisai Co., Ltd.
F2G Ltd
iCo Therapeutics Inc.
MABLife S.A.S
Merck & Co., Inc.
Nanomerics Ltd
Novabiotics Ltd
Pulmocide Ltd
Scynexis, Inc.
Sealife PHARMA GMBH
Sigma-Tau S.p.A.
Vical Incorporated
Aspergillosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
amphotericin b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amphotericin b NanoDisk - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-2397 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-9726 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AUGC-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AUGC-15 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-016 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-1210 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-1211 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
F-901318 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FK506 Analogues - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GBV-042 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
isavuconazonium sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KB-425796C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MAT-401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDN-0018 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NP-339 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
posaconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PTX-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SCY-078 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SLP-0901 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SLP-0904 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Aspergillosis and Candidiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Fungal Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Fungal Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Invasive Pulmonary Aspergillosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit ABC Transporter for Fungal Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aspergillosis - Recent Pipeline Updates
Aspergillosis - Dormant Projects
Aspergillosis - Dormant Projects
Aspergillosis - Discontinued Products
Aspergillosis - Product Development Milestones
Featured News & Press Releases
Apr 27, 2015: Astellas Launches CRESEMBA (isavuconazonium sulfate) in the United States for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis
Apr 23, 2015: CRESEMBA (isavuconazonium sulfate) Data to be Presented at the European Congress of Clinical Microbiology and Infectious Diseases
Mar 25, 2015: Vical Expands Infectious Disease Portfolio With Novel Antifungal From Astellas
Mar 06, 2015: FDA approves new antifungal drug Cresemba
Jan 22, 2015: Astellas Announces FDA Anti-Infective Drugs Advisory Committee Recommends Approval of CRESEMBA (isavuconazonium) for Treatment of Invasive Aspergillosis and Mucormycosis
Jan 09, 2015: SCYNEXIS Receives FDA Fast Track Designation for Oral Formulation of SCY-078 for the Treatment of Patients With Invasive Fungal Infections
Nov 21, 2014: Basilea Reports That U.S. FDA Sets Date Of Advisory Committee Meeting On Isavuconazole NDA For The Treatment Of Invasive Aspergillosis And Mucormycosis
Sep 09, 2014: F2G Announces A Major Funding Award From The Technology Strategy Board`s Biomedical Catalyst
Sep 06, 2014: Astellas Receives Notification from FDA of Acceptance of Filing of Isavuconazole NDA for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis
Sep 05, 2014: Astellas to Showcase Isavuconazole Data at ICAAC
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Aspergillosis, H1 2015
Number of Products under Development for Aspergillosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Aspergillosis - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2015
Aspergillosis - Pipeline by Astellas Pharma Inc., H1 2015
Aspergillosis - Pipeline by Aureogen Biosciences, Inc., H1 2015
Aspergillosis - Pipeline by Basilea Pharmaceutica AG, H1 2015
Aspergillosis - Pipeline by Biomar Microbial Technologies, H1 2015
Aspergillosis - Pipeline by Eisai Co., Ltd., H1 2015
Aspergillosis - Pipeline by F2G Ltd, H1 2015
Aspergillosis - Pipeline by iCo Therapeutics Inc., H1 2015
Aspergillosis - Pipeline by MABLife S.A.S, H1 2015
Aspergillosis - Pipeline by Merck & Co., Inc., H1 2015
Aspergillosis - Pipeline by Nanomerics Ltd, H1 2015
Aspergillosis - Pipeline by Novabiotics Ltd, H1 2015
Aspergillosis - Pipeline by Pulmocide Ltd, H1 2015
Aspergillosis - Pipeline by Scynexis, Inc., H1 2015
Aspergillosis - Pipeline by Sealife PHARMA GMBH, H1 2015
Aspergillosis - Pipeline by Sigma-Tau S.p.A., H1 2015
Aspergillosis - Pipeline by Vical Incorporated, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Aspergillosis Therapeutics - Recent Pipeline Updates, H1 2015
Aspergillosis - Dormant Projects, H1 2015
Aspergillosis - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Aspergillosis, H1 2015
Number of Products under Development for Aspergillosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report